Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miyazawa, I.
Right arrow Articles by Itoyama, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miyazawa, I.
Right arrow Articles by Itoyama, Y.
Related Collections
Right arrow All Immunology
Right arrow Autoimmune diseases
Right arrow Multiple sclerosis
Right arrow Devic's syndrome
NEUROLOGY 2007;68:865-867
© 2007 American Academy of Neurology

High CSF neurofilament heavy chain levels in neuromyelitis optica

I. Miyazawa, MD, I. Nakashima, MD, PhD, A. Petzold, MD, PhD, K. Fujihara, MD, PhD, S. Sato, MD, PhD and Y. Itoyama, MD, PhD

From the Department of Neurology (I.M., I.N., K.F., Y.I.), Tohoku University School of Medicine, and Department of Neurology (S.S.), Kohnan Hospital, Sendai, Japan; and Department of Neuroinflammation (A.P.), Institute of Neurology, University College London, UK.

Address correspondence and reprint requests to Dr. I. Nakashima, Department of Neurology, Tohoku University School of Medicine, 1-1 Seiryo-machi, Aoba-ku Sendai 980-8574, Japan; e-mail: inakashima{at}em.neurol.med.tohoku.ac.jp

The neurofilament heavy chain (NfHSMI35), a biomarker of axonal damage in the CSF, was measured in patients with neuromyelitis optica (NMO) and multiple sclerosis (MS). Significantly high CSF NfHSMI35 levels (>0.73 ng/mL) were found in 6 of 24 (25%) of the patients with NMO but none of the patients with MS (0/24). This finding suggests that axonal damage is more severe in NMO than in MS.

Supported by a grant-in-aid for general scientific research from the Japanese Ministry of Education, Science, and Culture and a grant from the Neuroimmunological Research Committee of the Japanese Ministry of Health, Labor, and Welfare.

Disclosure: The authors report no conflicts of interest.

Received May 25, 2006. Accepted in final form November 13, 2006.




This article has been cited by other articles:


Home page
 J. Neurol. Neurosurg. PsychiatryHome page
T Misu, R Takano, K Fujihara, T Takahashi, S Sato, and Y Itoyama
Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker
J. Neurol. Neurosurg. Psychiatry, May 1, 2009; 80(5): 575 - 577.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by AAN Enterprises, Inc.